About Us Services Careers FAQ Contact Us 0
Home Medical Devices Neurology Clinical Trials Market Size, Share & Drivers, 2033
Neurology Clinical Trials Market

Neurology Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional, Observational, Expanded Access), By Indication (Epilepsy, Parkinson's Disease (PD), Huntington's Disease, Stroke, Traumatic Brain Injury (TBI), Amyotrophic Lateral Sclerosis (ALS), Muscle regeneration, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2025-2033

Report Code: SRMD2946DR
Author : Debashree Bora
Buy Now
File Formats

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Neurology Clinical Trials Market Introduction
    2. By Phase
      1. Introduction
        1. Phase By Value
      2. Phase I
        1. By Value
      3. Phase II
        1. By Value
      4. Phase III
        1. By Value
      5. Phase IV
        1. By Value
    3. By Study Design
      1. Introduction
        1. Study Design By Value
      2. Interventional
        1. By Value
      3. Observational
        1. By Value
      4. Expanded Access
        1. By Value
    4. By Indication
      1. Introduction
        1. Indication By Value
      2. Epilepsy
        1. By Value
      3. Parkinson's Disease (PD)
        1. By Value
      4. Huntington's Disease
        1. By Value
      5. Stroke
        1. By Value
      6. Traumatic Brain Injury (TBI)
        1. By Value
      7. Amyotrophic Lateral Sclerosis (ALS)
        1. By Value
      8. Muscle regeneration
        1. By Value
      9. Others
        1. By Value
    1. Introduction
    2. By Phase
      1. Introduction
        1. Phase By Value
      2. Phase I
        1. By Value
      3. Phase II
        1. By Value
      4. Phase III
        1. By Value
      5. Phase IV
        1. By Value
    3. By Study Design
      1. Introduction
        1. Study Design By Value
      2. Interventional
        1. By Value
      3. Observational
        1. By Value
      4. Expanded Access
        1. By Value
    4. By Indication
      1. Introduction
        1. Indication By Value
      2. Epilepsy
        1. By Value
      3. Parkinson's Disease (PD)
        1. By Value
      4. Huntington's Disease
        1. By Value
      5. Stroke
        1. By Value
      6. Traumatic Brain Injury (TBI)
        1. By Value
      7. Amyotrophic Lateral Sclerosis (ALS)
        1. By Value
      8. Muscle regeneration
        1. By Value
      9. Others
        1. By Value
    5. U.S.
      1. By Phase
        1. Introduction
          1. Phase By Value
        2. Phase I
          1. By Value
        3. Phase II
          1. By Value
        4. Phase III
          1. By Value
        5. Phase IV
          1. By Value
      2. By Study Design
        1. Introduction
          1. Study Design By Value
        2. Interventional
          1. By Value
        3. Observational
          1. By Value
        4. Expanded Access
          1. By Value
      3. By Indication
        1. Introduction
          1. Indication By Value
        2. Epilepsy
          1. By Value
        3. Parkinson's Disease (PD)
          1. By Value
        4. Huntington's Disease
          1. By Value
        5. Stroke
          1. By Value
        6. Traumatic Brain Injury (TBI)
          1. By Value
        7. Amyotrophic Lateral Sclerosis (ALS)
          1. By Value
        8. Muscle regeneration
          1. By Value
        9. Others
          1. By Value
    6. Canada
    1. Introduction
    2. By Phase
      1. Introduction
        1. Phase By Value
      2. Phase I
        1. By Value
      3. Phase II
        1. By Value
      4. Phase III
        1. By Value
      5. Phase IV
        1. By Value
    3. By Study Design
      1. Introduction
        1. Study Design By Value
      2. Interventional
        1. By Value
      3. Observational
        1. By Value
      4. Expanded Access
        1. By Value
    4. By Indication
      1. Introduction
        1. Indication By Value
      2. Epilepsy
        1. By Value
      3. Parkinson's Disease (PD)
        1. By Value
      4. Huntington's Disease
        1. By Value
      5. Stroke
        1. By Value
      6. Traumatic Brain Injury (TBI)
        1. By Value
      7. Amyotrophic Lateral Sclerosis (ALS)
        1. By Value
      8. Muscle regeneration
        1. By Value
      9. Others
        1. By Value
    5. U.K.
      1. By Phase
        1. Introduction
          1. Phase By Value
        2. Phase I
          1. By Value
        3. Phase II
          1. By Value
        4. Phase III
          1. By Value
        5. Phase IV
          1. By Value
      2. By Study Design
        1. Introduction
          1. Study Design By Value
        2. Interventional
          1. By Value
        3. Observational
          1. By Value
        4. Expanded Access
          1. By Value
      3. By Indication
        1. Introduction
          1. Indication By Value
        2. Epilepsy
          1. By Value
        3. Parkinson's Disease (PD)
          1. By Value
        4. Huntington's Disease
          1. By Value
        5. Stroke
          1. By Value
        6. Traumatic Brain Injury (TBI)
          1. By Value
        7. Amyotrophic Lateral Sclerosis (ALS)
          1. By Value
        8. Muscle regeneration
          1. By Value
        9. Others
          1. By Value
    6. Germany
    7. France
    8. Spain
    9. Italy
    10. Russia
    11. Nordic
    12. Benelux
    13. Rest of Europe
    1. Introduction
    2. By Phase
      1. Introduction
        1. Phase By Value
      2. Phase I
        1. By Value
      3. Phase II
        1. By Value
      4. Phase III
        1. By Value
      5. Phase IV
        1. By Value
    3. By Study Design
      1. Introduction
        1. Study Design By Value
      2. Interventional
        1. By Value
      3. Observational
        1. By Value
      4. Expanded Access
        1. By Value
    4. By Indication
      1. Introduction
        1. Indication By Value
      2. Epilepsy
        1. By Value
      3. Parkinson's Disease (PD)
        1. By Value
      4. Huntington's Disease
        1. By Value
      5. Stroke
        1. By Value
      6. Traumatic Brain Injury (TBI)
        1. By Value
      7. Amyotrophic Lateral Sclerosis (ALS)
        1. By Value
      8. Muscle regeneration
        1. By Value
      9. Others
        1. By Value
    5. China
      1. By Phase
        1. Introduction
          1. Phase By Value
        2. Phase I
          1. By Value
        3. Phase II
          1. By Value
        4. Phase III
          1. By Value
        5. Phase IV
          1. By Value
      2. By Study Design
        1. Introduction
          1. Study Design By Value
        2. Interventional
          1. By Value
        3. Observational
          1. By Value
        4. Expanded Access
          1. By Value
      3. By Indication
        1. Introduction
          1. Indication By Value
        2. Epilepsy
          1. By Value
        3. Parkinson's Disease (PD)
          1. By Value
        4. Huntington's Disease
          1. By Value
        5. Stroke
          1. By Value
        6. Traumatic Brain Injury (TBI)
          1. By Value
        7. Amyotrophic Lateral Sclerosis (ALS)
          1. By Value
        8. Muscle regeneration
          1. By Value
        9. Others
          1. By Value
    6. Korea
    7. Japan
    8. India
    9. Australia
    10. Taiwan
    11. South East Asia
    12. Rest of Asia-Pacific
    1. Introduction
    2. By Phase
      1. Introduction
        1. Phase By Value
      2. Phase I
        1. By Value
      3. Phase II
        1. By Value
      4. Phase III
        1. By Value
      5. Phase IV
        1. By Value
    3. By Study Design
      1. Introduction
        1. Study Design By Value
      2. Interventional
        1. By Value
      3. Observational
        1. By Value
      4. Expanded Access
        1. By Value
    4. By Indication
      1. Introduction
        1. Indication By Value
      2. Epilepsy
        1. By Value
      3. Parkinson's Disease (PD)
        1. By Value
      4. Huntington's Disease
        1. By Value
      5. Stroke
        1. By Value
      6. Traumatic Brain Injury (TBI)
        1. By Value
      7. Amyotrophic Lateral Sclerosis (ALS)
        1. By Value
      8. Muscle regeneration
        1. By Value
      9. Others
        1. By Value
    5. UAE
      1. By Phase
        1. Introduction
          1. Phase By Value
        2. Phase I
          1. By Value
        3. Phase II
          1. By Value
        4. Phase III
          1. By Value
        5. Phase IV
          1. By Value
      2. By Study Design
        1. Introduction
          1. Study Design By Value
        2. Interventional
          1. By Value
        3. Observational
          1. By Value
        4. Expanded Access
          1. By Value
      3. By Indication
        1. Introduction
          1. Indication By Value
        2. Epilepsy
          1. By Value
        3. Parkinson's Disease (PD)
          1. By Value
        4. Huntington's Disease
          1. By Value
        5. Stroke
          1. By Value
        6. Traumatic Brain Injury (TBI)
          1. By Value
        7. Amyotrophic Lateral Sclerosis (ALS)
          1. By Value
        8. Muscle regeneration
          1. By Value
        9. Others
          1. By Value
    6. Turkey
    7. Saudi Arabia
    8. South Africa
    9. Egypt
    10. Nigeria
    11. Rest of MEA
    1. Introduction
    2. By Phase
      1. Introduction
        1. Phase By Value
      2. Phase I
        1. By Value
      3. Phase II
        1. By Value
      4. Phase III
        1. By Value
      5. Phase IV
        1. By Value
    3. By Study Design
      1. Introduction
        1. Study Design By Value
      2. Interventional
        1. By Value
      3. Observational
        1. By Value
      4. Expanded Access
        1. By Value
    4. By Indication
      1. Introduction
        1. Indication By Value
      2. Epilepsy
        1. By Value
      3. Parkinson's Disease (PD)
        1. By Value
      4. Huntington's Disease
        1. By Value
      5. Stroke
        1. By Value
      6. Traumatic Brain Injury (TBI)
        1. By Value
      7. Amyotrophic Lateral Sclerosis (ALS)
        1. By Value
      8. Muscle regeneration
        1. By Value
      9. Others
        1. By Value
    5. Brazil
      1. By Phase
        1. Introduction
          1. Phase By Value
        2. Phase I
          1. By Value
        3. Phase II
          1. By Value
        4. Phase III
          1. By Value
        5. Phase IV
          1. By Value
      2. By Study Design
        1. Introduction
          1. Study Design By Value
        2. Interventional
          1. By Value
        3. Observational
          1. By Value
        4. Expanded Access
          1. By Value
      3. By Indication
        1. Introduction
          1. Indication By Value
        2. Epilepsy
          1. By Value
        3. Parkinson's Disease (PD)
          1. By Value
        4. Huntington's Disease
          1. By Value
        5. Stroke
          1. By Value
        6. Traumatic Brain Injury (TBI)
          1. By Value
        7. Amyotrophic Lateral Sclerosis (ALS)
          1. By Value
        8. Muscle regeneration
          1. By Value
        9. Others
          1. By Value
    6. Mexico
    7. Argentina
    8. Chile
    9. Colombia
    10. Rest of LATAM
    1. Neurology Clinical Trials Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. IQVIA
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Novartis
    3. Covance
    4. Medpace
    5. Charles River Laboratories
    6. SyneousHealth
    7. Icon Plc
    8. GlaxoSmithKline
    9. Aurora healthcare
    10. Biogen
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Related Reports

Global Report
Market OverviewThe global pediatric clinical trials market size was valued at USD 15.87 billion in 2023 and it is projected to reach at USD 25.13 billion by 2032, increasing at a CAGR of 6.2% from 2024 to 2032. For a variety of indications that
Buy Now

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

We are featured on :

www.straitsresearch.com
© Copyright 2025. All rights Reserved.